The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Strengthening capabilities in Peptide Therapeutics and CDMO services
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
EBITDA margins expand to 31.3%
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure
Subscribe To Our Newsletter & Stay Updated
